Suppr超能文献

临床挑战:新型原发性免疫缺陷综合征患者的识别

Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.

作者信息

Buchbinder David, Seppanen Mikko, Rao V Koneti, Uzel Gulbu, Nugent Diane

机构信息

Division of Hematology, CHOC Children's Hospital, Orange, CA.

Helsinki University, Central Hospital, Helsinki, Finland.

出版信息

J Pediatr Hematol Oncol. 2018 Jul;40(5):e319-e322. doi: 10.1097/MPH.0000000000001003.

Abstract

Novel primary immunodeficiency disorders are being identified with next generation sequencing technologies. We describe 1 patient with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) haploinsufficiency who had recurrent enhancing brain lesions, nodular pulmonary infiltrates, hepatosplenomegaly, immune cytopenias, as well as progressive hypogammaglobulinemia and lymphopenia. We describe a second patient with activated p110δ syndrome (APDS)/p110δ activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) in association with recurrent respiratory tract infections, Epstein-Barr virus infection, lymphadenopathy, elevated serum IgM, and progressive lymphopenia. These presentations highlight the need for astute clinical judgment in the evaluation of patients with potential primary immunodeficiency disorders.

摘要

新型原发性免疫缺陷疾病正通过新一代测序技术得以识别。我们描述了1例细胞毒性T淋巴细胞相关蛋白4(CTLA-4)单倍体不足的患者,该患者有复发性强化脑病变、结节性肺部浸润、肝脾肿大、免疫性血细胞减少,以及进行性低丙种球蛋白血症和淋巴细胞减少。我们还描述了第2例患有活化的p110δ综合征(APDS)/p110δ激活突变导致衰老T细胞、淋巴结病和免疫缺陷(PASLI)的患者,其伴有复发性呼吸道感染、爱泼斯坦-巴尔病毒感染、淋巴结病、血清IgM升高和进行性淋巴细胞减少。这些表现凸显了在评估潜在原发性免疫缺陷疾病患者时敏锐临床判断的必要性。

相似文献

1
Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.
J Pediatr Hematol Oncol. 2018 Jul;40(5):e319-e322. doi: 10.1097/MPH.0000000000001003.
2
Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8 T Cell Survival, Differentiation, and Function.
Front Immunol. 2018 Aug 2;9:1758. doi: 10.3389/fimmu.2018.01758. eCollection 2018.
3
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
J Allergy Clin Immunol. 2016 Jul;138(1):210-218.e9. doi: 10.1016/j.jaci.2016.03.022. Epub 2016 Apr 21.
4
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Front Immunol. 2018 Mar 5;9:338. doi: 10.3389/fimmu.2018.00338. eCollection 2018.
5
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16.
6
Exhaustion of the CD8 T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta.
Front Immunol. 2018 Mar 7;9:446. doi: 10.3389/fimmu.2018.00446. eCollection 2018.
7
Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
J Clin Immunol. 2018 Nov;38(8):854-863. doi: 10.1007/s10875-018-0568-x. Epub 2018 Nov 29.
8
Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Front Immunol. 2018 Apr 5;9:568. doi: 10.3389/fimmu.2018.00568. eCollection 2018.
9
Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
Front Immunol. 2018 Feb 23;9:237. doi: 10.3389/fimmu.2018.00237. eCollection 2018.

引用本文的文献

2
Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
Orphanet J Rare Dis. 2025 May 3;20(1):212. doi: 10.1186/s13023-025-03734-z.
4
Systematic review of mortality and survival rates for APDS.
Clin Exp Med. 2024 Jan 27;24(1):17. doi: 10.1007/s10238-023-01259-y.
5
Two neurologic facets of CTLA4-related haploinsufficiency.
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(4). doi: 10.1212/NXI.0000000000000751. Print 2020 Jul.
6
Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.
Front Immunol. 2018 Jun 22;9:1423. doi: 10.3389/fimmu.2018.01423. eCollection 2018.
7
Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.
Front Immunol. 2018 Mar 7;9:445. doi: 10.3389/fimmu.2018.00445. eCollection 2018.
8
Neurological syndromes driven by postinfectious processes or unrecognized persistent infections.
Curr Opin Neurol. 2018 Jun;31(3):318-324. doi: 10.1097/WCO.0000000000000553.

本文引用的文献

1
Advances in basic and clinical immunology in 2014.
J Allergy Clin Immunol. 2015 May;135(5):1132-41. doi: 10.1016/j.jaci.2015.02.037.
2
New treatments for inflammatory rheumatic disease.
Immunol Res. 2014 Dec;60(2-3):277-88. doi: 10.1007/s12026-014-8565-5.
3
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Nat Med. 2014 Dec;20(12):1410-1416. doi: 10.1038/nm.3746. Epub 2014 Oct 20.
4
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Science. 2014 Sep 26;345(6204):1623-1627. doi: 10.1126/science.1255904. Epub 2014 Sep 11.
5
Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.
Am J Transplant. 2014 Sep;14(9):1985-91. doi: 10.1111/ajt.12834. Epub 2014 Aug 6.
6
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
Mol Cancer Ther. 2014 May;13(5):1021-31. doi: 10.1158/1535-7163.MCT-13-0639. Epub 2014 Apr 18.
8
Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Science. 2013 Nov 15;342(6160):866-71. doi: 10.1126/science.1243292. Epub 2013 Oct 17.
9
Signaling by the phosphoinositide 3-kinase family in immune cells.
Annu Rev Immunol. 2013;31:675-704. doi: 10.1146/annurev-immunol-032712-095946. Epub 2013 Jan 16.
10
Clinical features that identify children with primary immunodeficiency diseases.
Pediatrics. 2011 May;127(5):810-6. doi: 10.1542/peds.2010-3680. Epub 2011 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验